Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2015

View Archived Issues

Tunable BTK inhibitors from Principia Biopharma show promise for autoimmune diseases

Fate Therapeutics establishes collaboration on NK cell-based cancer immunotherapeutics

Enumeral Biomedical updates pipeline progress

Five Prime and Inhibrx sign GITR antibody research collaboration and license agreement

Novogen's Anisina receives FDA orphan drug designation for neuroblastoma

Radius Health's RAD-1901 synergizes with other anticancer agents in breast cancer models

European Commission approves Evotaz for HIV-1 infection in adults

Johnson & Johnson highlights progress of second quarter 2015

Retinal degeneration model devised to test retinal sheet transplants

Protagonist Therapeutics raises funds to advance pipeline of oral peptide drugs

Kallikrein-11 shows potential as a brain tumor biomarker

Immunocore conducts European life sciences' largest private financing

Achaogen receives NIAID contract to develop novel antibacterials

Avineuro reports results from phase II trial of AVN-211 as schizophrenia adjuvant therapy

Bayer presents GnRH receptor antagonists

FDA grants QIDP designation to iclaprim for hospital-acquired pneumonia

Gilead discloses Na+ channel modulators

Merck & Co patents CETP inhibitors

Esteve divulges multimodal sigma1/mu-opioid receptor ligands

Amgen reports phase II trial results for blinatumomab in Ph+ ALL

Respivert and Topivert disclose protein kinase inhibitors

Yungjin Pharmaceutical starts phase IIa trial of YPL-001 for COPD

Mesenchymal stem cell-derived exosomes can enhance wound healing

New Approaches to Neuroblastoma Therapy consortium starts phase I trial of SF-1126

FDA approves Dysport for upper limb spasticity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...